Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
| Revenue | $290,403,000,000 |
| Net Income | $100,988,000,000 |
| Free Cash Flow | $69,659,000,000 |
| Book Value / Share | $32.22 |
| Total Liabilities | $322,309,000,000 |
| Total Equity | $143,486,000,000 |
| Debt / Equity | 0.72 |
| Current Ratio | 0.74 |
| Interest Coverage | 66.53 |
| Working Capital | $-56,631,000,000 |
Core multiples and valuation signals — useful to compare vs peers.
| P/E (TTM) | 27.53 |
| Industry P/E | N/A |
| Forward P/E | 13.94 |
| P/B | 19.38 |
| Price / Sales | 9.57 |
| P / FCF | 39.91 |
| EV / EBITDA | 20.87 |
| Graham Number | $128.20 |
| DCF (placeholder) | — |
| Gross Margin | 84.67% |
| Operating Margin | 44.19% |
| Net Margin | 34.78% |
| ROIC | 38.99% |
| Asset Turnover | 0.62 |
| RSI (14) | 46.29 |
| SMA 50 | 55.80 |
| SMA 200 | 69.10 |
| MACD | 0.14 |
| Signal | NEUTRAL |
| Name | Title |
|---|---|
| Mr. Karsten Munk Knudsen | Executive VP, CFO & Member of the Management Board (1971) |
| Mr. Maziar Mike Doustdar | President, CEO & Member of the Management Board (1970) |
| Mr. Henrik Ehlers Wulff | Executive VP of CMC & Product Supply and Member of the Management Board (1970) |
| Mr. Ludovic Helfgott | Executive VP of Product & Portfolio Strategy and Member of Management Board (1974) |
| Dr. Martin Holst Lange | EVP of R&D, CSO and Member of the Management Board (1970) |
| Ms. Tania Sabroe | EVP of People, Organisation and Corporate Affairs & Member of Management Board (1977) |
| Mr. David S. Moore | Executive VP of US Operations & Member of Management Board (1974) |
| Ms. Thilde Hummel Bogebjerg | Executive VP of Quality, IT & Environmental Affairs and Member of Management Board (—) |
Eli Lilly and Company's strong Phase 3 diabetes drug results boost its GLP-1 franchise. Click for my updated look at LLY stock following the latest data.
The Value Fund finished the third quarter +4.0%, bringing our year-to-date return to +0.2% net of fees and expenses. Read more here.